1Yoshizaki T, Maruyama Y, Sato H, et al.Expression of tissue inhibitor of matrix metalloproteinase-2 correlates with activation of matrix metalloproteinase-2 and predicts poor prognosis in tongue squamous cell carcinoma. Int J Cancer, 2001, 95: 44-50.
2Fleischmajer R, Kuroda K, Hazan R, et al.Basement membrane alterations in psoriasis are accompanied by epidermal overexpression of MMP-2 and its inhibitor TIMP-2. J Invest Dermatol, 2000, 115: 771-777.
3Vasku V, Vasku A, Tschoplova S, et al.Genotype association of C (-735)T polymorphism in matrix metalloproteinase 2 gene with G (8002)A endothelin 1 gene with plaque psoriasis. Dermatology, 2002, 204:262-265.
4Sawa M, Tsukamoto T, Kiyoi T, et al. New strategy for antedrug application: development of metalloproteinase inhibitors as antipsoriatic drugs. J Med Chem, 2002, 45:930-936.
4[2]Takahashi H, Manabe A, Ishida Yamamoto A, et al. Aberrantex pression of apoptosis related molecules in psoriatic epidermis [J].Drmatol Sci,2002,28 ( 3 ): 187 -97.
5[3]Vasku V, Vasku A, Tschoplova, et al. Genotype association of c (-735 ) T polymorphism in MMP-2 gene with G (8002)A endothelin,gene with plaque psoriasis [J]. Dermatology,2002,204 (4):262-265.
6[4]Tanaka M, Itai T, Adachi M, et al. Downregulation of Fas ligand by shedding[J]. Nat Med,1998,(4):31-36.
7[5]Hahne M, Rimoldi D,Schroter M,et al. Melanom cell expression of Fas (APO-1/CD95)ligand:Implications for tumor immue escape[J].Science, 1996,274:1363-1366.
8[4]Giannelli G,Erriquez R,Iannone F.MMP-2,MMP-9,TIMP-1 and TIMP-2 levels in patients with rheumatoid arthritis and psoriatic arthritis[J].Clin Exp Rheumatol,2004,22:335-338.
9[5]Fleisehmajer R.The study of MMP-2,TIMP-2 in psoriatic and nonpsoriatic skin[J].J Invest Dermatol,2000,115:771-777.
10[6]Zhang DH,Marconi A,Xu LM.Tripterine inhibits the expression of adhesion molecules in activated endothelial cells[J].J Leukoc Biol,2006,80:309-319.
